QNZ (EVP4593): Potent NF-κB Inhibitor for Inflammation & Neurodegeneration

Executive Summary: QNZ (EVP4593) is a highly potent NF-κB inhibitor (IC₅₀ = 11 nM in Jurkat T cells) supplied by APExBIO, enabling precise dissection of inflammatory signaling mechanisms (APExBIO). It is a quinazoline derivative identified via luciferase reporter gene assays and effectively inhibits PMA/PHA-induced NF-κB activation and TNF-α production (IC₅₀ = 7 nM) (Yang et al., 2025). QNZ displays robust anti-inflammatory activity in vivo, including edema reduction in a rat paw model. Its solubility profile supports experimental flexibility, and it has demonstrated neuroprotective effects in Drosophila models of Huntington’s disease. QNZ is widely adopted for NF-κB pathway modulation, inflammation research, and neurodegenerative disease models.

Biological Rationale

The NF-κB signaling pathway orchestrates inflammatory and immune responses in diverse physiological and pathological contexts (Yang et al., 2025). Dysregulation of NF-κB is implicated in chronic inflammatory diseases, infection persistence, and neurodegenerative disorders such as Huntington’s disease (HD). In osteomyelitis, persistent Staphylococcus aureus infection induces local inflammation and fibrosis, compromising vascular perfusion and antibiotic efficacy. Targeting NF-κB can disrupt this pathogenic cycle, offering therapeutic and experimental leverage (QNZ: Potent Quinazoline NF-κB Inhibitor for Inflammation). QNZ (EVP4593), as a selective quinazoline derivative NF-κB inhibitor, is designed for high-fidelity pathway suppression in cellular and animal models.

Mechanism of Action of QNZ (EVP4593)

QNZ (EVP4593) directly inhibits the transcriptional activation of NF-κB, a master regulator of inflammatory gene expression. In human Jurkat T cells, QNZ exhibits an IC₅₀ of 11 nM for NF-κB inhibition, as measured by luciferase reporter assay. It blocks PMA/PHA-induced NF-κB activation and suppresses TNF-α production (IC₅₀ = 7 nM). Mechanistically, QNZ attenuates the expression of NF-κB target genes, reducing downstream inflammatory mediators and cell recruitment. In models of neurodegeneration such as Drosophila HD, QNZ at 300 nM reduces store-operated calcium entry (SOC), which is implicated in neuronal toxicity (Advanced Mechanisms and Novel Applications—this article extends by detailing SOC modulation and solubility parameters). QNZ is insoluble in water but soluble in ethanol (≥10.06 mg/mL) and DMSO (≥15.05 mg/mL), supporting flexible experimental design.

Evidence & Benchmarks

• QNZ (EVP4593) inhibits NF-κB activation in human Jurkat T cells with an IC₅₀ of 11 nM (luciferase assay; APExBIO product page).
• Suppresses PMA/PHA-induced TNF-α production in vitro with an IC₅₀ of 7 nM (APExBIO).
• Reduces paw edema formation in rat carrageenin-induced inflammation model, indicating significant anti-inflammatory activity (Yang et al., 2025).
• At 300 nM, attenuates SOC influx in neuronal cultures, relevant to Huntington's disease pathology (QNZ: Potent NF-κB Inhibitor for Translational Research—this article updates with detailed solubility and dosing guidance).
• Demonstrates neuroprotective effects by slowing motor decline in Drosophila HD models without observed toxicity (Advanced Mechanisms and Novel Applications).
• Solubility: ≥15.05 mg/mL in DMSO, ≥10.06 mg/mL in ethanol (ultrasonication recommended); insoluble in water (APExBIO).

Applications, Limits & Misconceptions

QNZ (EVP4593) is employed in:

• Cellular models for dissecting NF-κB pathway activation and its downstream gene expression.
• In vivo models of acute and chronic inflammation, including paw edema and osteomyelitis-related fibrosis (Yang et al., 2025).
• Neurodegenerative disease models (e.g., Huntington’s disease) for exploring NF-κB-dependent neuronal toxicity and calcium homeostasis.
• Pharmacological studies targeting NF-κB in infection, inflammation, and tissue remodeling (Reliable NF-κB Inhibition for Cell-Based Assays—this article clarifies dosing and storage best practices for reproducibility).

Common Pitfalls or Misconceptions

• QNZ is not soluble in water; attempts to dissolve in aqueous buffers lead to precipitation and reduced bioactivity.
• It is not a pan-cytokine inhibitor; its effects are specific to NF-κB-dependent pathways.
• Long-term storage of QNZ solutions at room temperature leads to degradation; -20°C storage is required for stock solutions.
• QNZ does not directly eradicate pathogens such as S. aureus; it modulates host response pathways.
• In vivo efficacy and toxicity must be validated in each model system; Drosophila HD model findings may not generalize to mammals.

Workflow Integration & Parameters

For experimental use, QNZ (EVP4593) (A4217 kit) is typically reconstituted in DMSO or ethanol using ultrasonic assistance for optimal solubility. Warming at 37°C and brief sonication are recommended. Stock concentration is prepared at ≥10 mM and stored at -20°C. Working concentrations range from 7–300 nM, depending on cell type and assay (product page). Avoid repeated freeze-thaw cycles. In neuronal cultures, 300 nM attenuates SOC influx without affecting viability. For in vivo paw edema models, dosing and vehicle compatibility should be empirically validated. For detailed assay guidance, see also Potent Quinazoline NF-κB Inhibitor for Inflammation—this article provides updated solubility and workflow parameters.

Conclusion & Outlook

QNZ (EVP4593) is a validated, nanomolar-range NF-κB inhibitor with robust anti-inflammatory and neuroprotective activity. As a quinazoline derivative supplied by APExBIO, it sets a reproducibility benchmark for pathway-targeted studies in inflammation and neurodegeneration. Researchers should consider model-specific dosing, solubility, and storage criteria for optimal results. Ongoing studies will clarify its translational value across species and disease models, including infection-driven fibrosis and chronic neurodegeneration.